Antisense Therapy for Infectious Diseases
Journal Article
2023-08-21
Permanent link to this Item
Authors
Journal Title
Cells
Link to Journal
Journal ISSN
Volume Title
Publisher
Multidisciplinary Digital Publishing Institute
Publisher
Department
Faculty
Series
Abstract
Infectious diseases, particularly Tuberculosis (TB) caused by Mycobacterium tuberculosis, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases.
Description
Reference:
Buthelezi, L.A., Pillay, S., Ntuli, N.N., Gcanga, L. & Guler, R. 2023. Antisense Therapy for Infectious Diseases. Cells. 12(16):2119. http://hdl.handle.net/11427/38762